Lung/ Chest Cancer Studies Currently Recruiting Participants at the University of Chicago Medicine Comprehensive Cancer Center

Study Number Title
13473A Utilization of Previously Banked Tissue from Patients with Lung Cancer, Mesothelioma, Thymoma/Thymic Carcinoma, and Esophageal Cancer and Correlation with Clinical Data.
9571 Tissue Procurement for Lung Cancer, Esophageal Cancer, Thymoma, and Mesothelioma in Patients Undergoing Surgery or Biopsy
15410A Utilization of Previously Banked Tissues from Patients with Head and Neck and Lung Cancer for Analysis of DNA repair markers and Correlation With Clinical Data
Select
16206B CALGB 30610: PHASE III COMPARISON OF THORACIC RADIOTHERAPY REGIMENS IN PATIENTS WITH LIMITED SMALL CELL LUNG CANCER ALSO RECEIVING CISPLATIN AND ETOPOSIDE
Select
16262B IRB 16262B: CALGB 140503: A Phase III Randomized Trial of Lobectomy versus Sublobar Resection for Small (≤ 2 cm) Peripheral Non-Small Cell Lung Cancer
13876B Use of Tissue from Tissue Bank Based on Protocols 9571A and 13473A for Building of Tissue Arrays, Immunhistochemistry, Mutational Analysis, and Raising of Cell Lines
15995B Tissue and Blood Procurement from Non-Cancer 1st degree relatives for comparison to Tissue and Blood from patients with Primary Aerodigestive Cancers
16110E Role of c-Met in SCLC and potential for Novel Therapy
16057A A Long Term Investigation of Radiation Treatment in Lung Cancer Patients
16093A Investigating Radiation Pneumonitis Genetics
16723A Evaluation of EGFR response and duration in African American patients with NSCLC
17018B Investigation of Gene Expression Profiles in Primary and Metastatic tumors in Patients with Surgically Resected Lung Metastases
Select
10-290-A CALGB 30901 Randomized Phase II Study of Maintenance Pemetrexed Versus Observation for Patients with Malignant Pleural Mesothelioma without Progression after First-Line Chemotherapy
10-654-N A Project to Study Banked Tissue from Deceased Patients with Various Malignancies, Especially Aerodigestive Malignancies
Select
IRB14-0894 A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of MOXR0916 Administered Intravenously as a Single Agent to Patients with Locally Advanced or Metastatic Solid Tumors
13-0002 A Registry for Serial Imaging and Plasma Assessment in Advanced Solid Tumor Patients
IRB13-0673 Retrospective Review of Unusual Cases of Esophageal Cancer
Select
IRB13-0936 A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors
Select
IRB13-1233 A Pilot Investigation to Examine the Effect of a Multi-Media, Computer Based Tool (Talking Touchscreen) on Enrollment in Adult Oncology-Specific Clinical Trials at an Academic Medical Center
Select
IRB14-0081 Phase I, Multicenter, Cohort Dose Escalation Trial to Determine the Safety, Tolerance, and Maximum Tolerated Dose of DCR-MYC, a Lipid Nanoparticle (LNP)-Formulated Small Inhibitory RNA (siRNA) Oligonucleotide Targeting MYC, in Patients with Refractory Locally Advanced or Metastatic Solid Tumor Malignancies, Multiple Myeloma, or Lymphoma
Select
IRB14-0133 A Phase III, randomized, open-label, cross-over, multi-center, safety and efficacy study to evaluate nab-paclitaxel (Abraxane) as maintenance treatment after induction with nab-paclitaxel plus carboplatin in subjects with squamous cell non-small cell lung cancer (NSCLC)
Select
IRB14-0432 A Phase Ib Study of the Safety and Pharmacology of MPDL3280A Administered with Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer
Select
IRB14-0818 Open-Label Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Daily Oral MGCD265 Administered Without Interruption to Patients with Advanced Malignancies
Select
IRB13-1037 RTOG 1306: A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-Small Cell Lung Cancer (NSCLC)
Select
CIRB14-0811 NRG-BR001: Phase 1 Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple Metastases
Select
IRB14-1304 A Phase 1 Dose Escalation and Phase 2 Randomized, Placebo Controlled Study of the Efficacy and Tolerability of Veliparib in Combination with Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Subjects with Stage III Non-Small Cell Lung Cancer (NSCLC)
Select
IRB14-0987 A First-in-Human Phase 1, Dose Escalation, Safety and Pharmacokinetic Study of PF-06647020 in Adult Patients with Advanced Solid Tumors
Select
CIRB14-1151 E4512: A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Select
IRB15-0242 A Phase 1b/2 Study of OMP-59R5 in Combination with Etoposide and Platinum Therapy in Subjects with Untreated Extensive Stage Small Cell Lung Cancer
Select
CIRB14-1149 A081105: Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Select
IRB14-0704 A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Solid Tumors
Select
IRB15-0395 A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy and Safety of MPDL3280A (Anti-PD-L1 Antibody) in Combination with Carboplatin + Paclitaxel or MPDL3280A in Combination with Carboplatin + Nab-Paclitaxel versus Carboplatin + Nab-Paclitaxel in Chemotherapy-Na´ve Patients with Stage IV Squamous Non-Small Cell Lung Cancer
Select
IRB15-0380 A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin + Paclitaxel With or Without Bevacizumab Compared With Carboplatin + Paclitexel + Bevacizumab In Chemotherapy-Naive Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer
Select
CIRB14-1150 A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Select
CIRB14-1570 S1400: Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer
Select
IRB14-1586 A Phase 2 Study of MM-121 in Combination with Docetaxel or Pemetrexed versus Docetaxel or Pemetrexed alone in Patients with Heregulin Positive, Non-Small Cell Lung Cancer
Select
IRB15-0091 An Open-label, Dose-escalation/expansion, Phase 1 Study of ASP4132, Given Orally to Subjects with Advanced Refractory Solid Tumors and Lymphoma
Select
IRB15-0835 A Phase 1/2 Dose Escalation and Cohort Expansion Study of the Safety and Tolerability of Urelumab Administered in Combination with Nivolumab in Advanced /Metastatic Solid Tumors and B Cell Non-Hodgkins Lymphoma
Select
IRB15-1130 Phase I study of PD1 blockade by pembrolizumab with stereotactic body radiotherapy in advanced solid tumors
Select
IRB15-0650 A Phase Ib/II Clinical Study of BBI608 Administered in Combination with Immune Checkpoint Inhibitors to Adult Patients with Advanced Cancers
IRB15-1022 A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of MOXR0916 and MPDL3280A in Patients with Locally Advanced or Metastatic Solid Tumors

To learn more about cancer clinical trials or to make an appointment, call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials). Although our objective is to provide an updated listing of clinical trials, please note that a listing here does not guarantee that a trial is open or available to any specific patient. Additional trials may be available that are not listed. Complete information is available only from a treating physician.
Are you part of the research staff and cannot see your study listed here? Please contact the cancer center IT team